What is Restless Leg Syndrome?

Restless leg syndrome (RLS) is a neurological disorder characterized by unpleasant or painful throbbing, pulling, or creeping sensations in the legs. RLS patients often feel irresistibly compelled to constantly move their legs, and these relentless symptoms can cause insomnia, emotional distress, and a significantly diminished quality of life.

RLS can be classified as primary or secondary; the exact cause of primary RLS is not known, although altered dopamine signaling is thought to play a part, while secondary RLS is connected to an underlying medical condition such as diabetes, chronic venous disorders, and iron deficiency.

Several natural interventions such as diosmin and folate may help relieve the symptoms or underlying causes of RLS.

What are the Causes and Risk Factors for Restless Leg Syndrome?

• Family history
• Kidney disease
• Diabetes/impaired glucose tolerance
• Chronic venous disorders
• Iron deficiency (or regularly donating blood)
• Pregnancy
• Sedentary lifestyle
• Obesity

What are Conventional Medical Treatments for Restless Leg Syndrome?

Note: Generally, RLS is not treated pharmacologically unless it is chronic, persistent, and unresponsive to nonpharmacologic treatments such as correcting iron deficiency and lifestyle changes. Also, treating primary RLS should not be considered until possible secondary causes are addressed.

• Dopamine agonists such as ropinirole, pramipexole, and rotigotine (Neupro)
• Levodopa, a dopamine precursor (usually for intermittent treatment)
• Benzodiazepines
• Gabapentin
• Low-dose opioids (typically a last resort)

What Lifestyle Changes Can Be Beneficial for Restless Leg Syndrome?

• Avoid stimulants such as nicotine and excessive caffeine
• Exercise regularly, but not right before bed
• Massage and acupuncture, in conjunction with medications or alone, may offer relief to some people with RLS

What Natural Interventions May Be Beneficial for Restless Leg Syndrome?

• Iron. Iron deficiency or altered brain iron metabolism have been linked to RLS; supplementation is often recommended for RLS patients who have been tested and shown to be deficient. Iron supplementation has been shown to significantly improve symptoms in iron-deficient RLS patients.
• Folate. Low levels of folate may play a role in RLS, especially in pregnant women. Pregnant women with lower folate levels were more likely to develop RLS than women who took vitamins during pregnancy.
• Magnesium. Low magnesium levels can cause excitability of neurons; magnesium supplements are often used to prevent abnormal activity in the nervous system. A case study indicated magnesium may improve symptoms and sleep problems associated with RLS.
• Diosmin. Diosmin is a natural flavone derivative often used for supporting venous function. Since venous disorders have been linked with RLS, diosmin is a promising possible treatment.
• Green coffee extract. Diabetes and pre-diabetes are known risk factors for RLS. Green coffee extract may help maintain healthy glucose levels.
• Valerian root. Valerian, an herbal sedative, is often used as a sleep aid. In a clinical trial, supplementation with valerian resulted in improvements in RLS symptoms and less daytime sleepiness.
• Other natural interventions that may help relieve RLS symptoms include D-ribose and vitamins C and E.

Restless legs syndrome (RLS) is a neurological disorder associated with impaired sleep and characterized by throbbing, pulling, creeping, or other unpleasant sensations in the legs. Patients with RLS often complain of an almost irresistible urge to move their legs. The relentless and tormenting course of RLS symptoms often significantly diminishes quality of life for many of those affected and leads to significant emotional distress (NINDS 2011).

Sleepless nights and mental anguish contribute to a considerable physical and psychological burden for those afflicted with RLS (restless legs syndrome). Unfortunately, drugs used to treat psychological effects associated with RLS, such as tricyclic antidepressants (TCAs) and selective serotonin uptake inhibitors (SSRIs), may trigger or worsen RLS symptoms (Pullen 2011; Lee 2008; Winkelmann 2005; Hornyak 2010).

Pharmaceutical treatment strategies, such as dopaminergic medications, can offer relief for those with RLS. However, a pitfall of dopaminergic drugs used at high doses is that quite often they may exacerbate RLS symptoms via a phenomenon known as augmentation or rebound. Fortunately, the 2012 approval of sustained release, transdermal rotigotine may overcome this roadblock (Bell 2012; Elshoff 2012; Boroojerdi 2010; Godau 2011).

Many people do not realize that RLS can be classified as primary or secondary. Primary RLS has no known cause, whereas secondary RLS is related to another medical ailment. For example, secondary RLS is often associated with high blood sugar related nerve damage or chronic vascular disease like deep vein thrombosis and arterial claudication (Gemignani 2007; McDonagh 2007).

In this protocol, you will learn about possible causes of RLS and discover that treatment strategies vary based on the origins of the condition. You will also learn about convenient blood tests that might help uncover unexpected secondary causes of RLS symptoms.

Primary RLS The exact cause of primary RLS is unknown. However, there does appear to be a genetic component as approximately 40 to 50 percent of patients with primary RLS have a family history of the disorder and certain genetic variations are associated with the condition (Ferri 2012; Bradley 2008; Miletic 2011).

Although many think of primary RLS as a disease of the peripheral nervous system, studies suggest that the central nervous system may also be involved. Because RLS is akin to some other movement disorders the neurotransmitter dopamine, which helps facilitate uniform, controlled movements, has been theorized to be a possible causative factor. Indeed, altered dopamine signaling within the brain has been observed in several RLS studies, but results have been insufficient to draw firm conclusions (Clemens 2006; Cervenka 2006; Ruottinen 2000; Turjanski 1999; Eisensehr 2001). Additionally, alterations in dopamine signaling in the spinal cord have been observed, which lends further support to the hypothesis that dopamine is involved in RLS (Paulus 2006; Clemens 2006).

Secondary RLS Over twenty medical conditions are connected to secondary RLS (Miletic 2011).

Secondary RLS is a common complication of end-stage kidney disease. Estimates indicate that up to 60% of patients on dialysis have RLS (Walker 1995; Thorp 2001; Kavanagh 2004). People with diabetes or impaired glucose tolerance are more likely to have RLS, and RLS is a prominent part of diabetic peripheral neuropathy (Bosco 2009; O’Hare 1994; Lopes 2005; Merlino 2007). RLS may also be associated with Parkinson’s disease, another disorder associated with dopaminergic dysfunction in the nervous system. However, the link has not yet been clearly established (Guerreiro 2010; Gjerstad 2011). People with RLS also have an increased risk of developing high blood pressure, possibly due to overactivity of certain parts of the nervous system (Walters 2009; Batool-Anwar 2011).

Chronic venous disorders are a major contributor to secondary RLS (McDonagh 2007). In a 2007 study, researchers found that 36% of patients suffering from chronic venous disease also had RLS. In comparison, the control group only had a 19% occurrence of RLS. However, when the control participants who showed positive for RLS were studied more closely, it was noted that 91% of them had mild indications of venous problems (McDonagh 2007). In another study, participants with RLS who received medical treatment for chronic venous disease reported a 36% increase in quality of sleep and a 67% decrease in severity of symptoms (Tison 2005).

Iron Dysregulation in RLS

Iron deficiency within the brain is currently recognized as a key mechanism in the development and severity of RLS (Mogavero 2026; Ferre 2019). The prevalence of RLS is nearly six-fold higher in individuals with nonanemic iron deficiency or iron deficiency anemia than the general population (Ferre 2019; Auerbach 2025; Song 2024). It appears that brain iron deficiency can also occur independently of systemic iron availability, as many RLS sufferers have normal blood levels of markers of iron status (Ferre 2019; Winkelman 2026).

Some evidence suggests RLS patients may have a defect in iron transport across the blood-brain barrier, possibly related to genetic factors (Wade 2019; Connor 2017). Results from an autopsy study (the gold standard of brain tissue assessment) showed subjects with RLS had markedly lower iron levels in a region of the brain called the substantia nigra (Connor 2003; Beliveau 2022). The substantia nigra releases dopamine and is involved in motor control (Salvatore 2024). Other studies have found cerebrospinal fluid levels of iron and ferritin (stored iron) were lower and levels of transferrin (an iron transport protein) were higher in patients with RLS compared with people without the condition (Earley 2000; Mizuno 2005).

A growing body of research shows brain iron deficiency is likely to affect multiple signaling pathways related to motor control and circadian rhythms. Animal research has indicated brain iron deficiency not only alters dopamine synthesis and signaling but also increases glutamate activity and impairs inhibitory control (Mogavero 2026). Glutamate is the brain’s primary excitatory neurotransmitter and is involved in arousal and the circadian sleep-wake cycle (Luo 2025). Imbalanced activation of dopamine and glutamate pathways may be caused by downregulated adenosine signaling that appears to be directly triggered by brain iron deficiency (Mogavero 2026). Adenosine’s function in the brain is incompletely understood but its role in regulating signaling linked to sleep-wake cycling and movement has recently been identified (Yahiro 2025).

RLS patients with known iron deficiency frequently improve with iron therapy. Iron supplementation has also been found to reduce symptoms in some RLS patients with normal ferritin levels (Yang 2019; Trotti 2019). Ferritin is the storage form of iron and is used to screen for iron deficiency, but also increases with inflammation. Therefore, iron status is best assessed in all RLS patients by testing ferritin and transferrin saturation (a measure of how much iron carrying capacity is occupied). Transferrin saturation is calculated using serum iron level and total iron binding capacity (the amount of iron carrying capacity available) (Elstrott 2020; Winkelman 2025). These tests are generally done in the morning after an overnight fast (NLM 2024). Appropriate iron therapy can be initiated based on these results.

There is no cure for RLS, but a number of non-pharmacologic and pharmacologic therapies have been found to be helpful in its management. Treatment begins with identifying possible contributing factors, such as certain medications (eg, antihistamines, antidepressants, and dopamine blockers) and untreated sleep apnea (Winkelman 2026; Silber 2021). Lifestyle strategies, such as reducing alcohol and caffeine intake, increasing aerobic exercise and lower limb strength training, stretching before bedtime, using warm baths or showers, and other sleep hygiene practices are often suggested (Winkelman 2026; Younas 2025).

Non-pharmacologic interventions like mind-body therapies and physical modalities may be helpful, particularly in cases of intermittent RLS. In persistent cases, pharmacologic interventions may be prescribed for as-needed or regular use (Winkelman 2026; Silber 2021). The response to medical treatment is individualized and many people change or stop their prescribed therapy within one year (Costales 2022). Notably, nearly 40% of RLS patients do not respond to medical treatment and others report experiencing ongoing symptoms (Winkelman 2026).

In 2025, the American Academy of Sleep Medicine (AASM) released a new set of expert consensus-driven recommendations to guide clinical decision-making for treating RLS (Winkelman 2025). While not universally embraced, its approach, which bases drug consideration on evidence regarding efficacy and safety, has been broadly welcomed by sleep organizations around the world (Ferri 2025).

Iron

Brain iron deficiency is a key contributor to RLS, and iron therapy has been shown to benefit some RLS patients—even those without anemia. The AASM currently recommends iron supplementation as first-line therapy for RLS patients with iron deficiency anemia as well as those without anemia whose ferritin levels are up to 100 ng/mL—a level that is normal in healthy people but may not ensure brain iron levels are adequate in those with RLS (Winkelman 2026; Winkelman 2025; Al-Naseem 2021). Specifically, oral iron is recommended for those whose serum ferritin concentrations are ≤75 ng/mL or transferrin saturation is <20% (indicating likely iron deficiency), whereas intravenous (IV) iron is preferred for those with ferritin levels between 75 and 100 ng/mL and transferrin saturation up to 45%, since iron absorption is inhibited by higher iron availability in the body (Winkelman 2026; Silber 2021). Intravenous iron may also be recommended for patients with digestive disorders that limit iron uptake, as well as those who do not tolerate or respond to oral iron. Ongoing iron therapy may or may not be helpful in managing RLS symptoms after ferritin levels reach 100 ng/mL (Silber 2021). Iron is not recommended for RLS patients with ferritin levels higher than 300 ng/mL or transferrin saturation higher than 45% (Winkelman 2026). The maximum symptom benefit may take one to three months, even with IV iron infusion.

Importantly, guidelines for iron therapy have yet to be validated and evidence is evolving. For example, a 2025 observational study that included data from 58 subjects with RLS found the response to IV iron therapy was similar in those with ferritin levels between 100 and 300 ng/mL and those with levels under 100 ng/mL (Garcia-Malo 2025). Another study that analyzed data from 164 RLS patients found lower transferrin saturation was correlated with better likelihood of responding to IV iron therapy, especially in women (Park 2020).

Oral Iron

Oral ferrous salts, such as ferrous sulfate, fumarate, and gluconate, are widely available and commonly prescribed to treat mild-to-moderate iron deficiency (Pantopoulos 2024). Randomized controlled trials in RLS patients have shown ferrous sulfate, at 325 mg (providing 65 mg elemental iron) twice daily, improved symptoms (Wang 2009; Short 2024). However, side effects related to poor absorption, such as nausea and constipation, are common and frequently limit the use of ferrous salts (Winkelman 2025; Pantopoulos 2024). A number of clinical trials have indicated alternate-day dosing leads to a higher absorption rate and reduces digestive side effects compared with more frequent dosing regimens. Alternative formulations, such as iron protein succinylate, may be more tolerable than ferrous salts, but are untested in RLS patients as of May 2026 (Pantopoulos 2024).

Intravenous Iron

Ferric carboxymaltose is the most studied form of IV iron in RLS treatment (Winkelman 2026). It is administered as one or two infusions totaling 1,000 mg (Winkelman 2026; Van Doren 2024). Randomized placebo-controlled trials have shown IV carboxymaltose improved RLS severity, sleep quality, and quality of life (Winkelman 2025).

Low molecular weight iron dextran and ferumoxytol are commonly used forms of IV iron, but have less evidence to support their use in treating RLS (Winkelman 2025). Low molecular weight iron dextran is administered in a single 1,000 mg infusion, which may be repeated if needed; ferumoxytol is typically given in two 510 mg doses three to eight days apart, but has also been shown to be safe and effective for restoring iron levels when given as a single 1,020 mg infusion (Winkelman 2026; Van Doren 2024). One trial in 94 RLS patients with iron deficiency anemia found IV ferumoxytol and oral ferrous sulfate were equally effective for reducing symptoms, but ferumoxytol caused fewer side effects and most were transient infusion reactions (Short 2024).

Intravenous iron therapy can cause dangerously low blood phosphate levels, or hypophosphatemia. Ferric carboxymaltose is more likely to cause hypophosphatemia than low molecular weight iron dextran or ferumoxytol, and the risk is higher in those with recurrent or ongoing blood loss or abnormal uterine bleeding. Infusion reactions, which are generally not dangerous, are relatively common with IV iron therapies. Conversely, allergic reactions, which can be serious or even fatal, are extremely rare (Van Doren 2024). Notably, although older IV iron dextran was associated with an alarming rate of serious allergic reactions, including potentially fatal anaphylaxis, low molecular weight iron dextran has not demonstrated the same allergenicity (Winkelman 2025; Van Doren 2024).

Gabapentinoids

Gabapentinoids (also known as alpha-2-delta calcium channel ligands) are recommended in the current AASM guidelines as first-line pharmacologic therapy for adults with frequent or persistent moderate-to-severe RLS (Winkelman 2025; Burini 2024). Gabapentinoids appear to reduce nerve hyperactivity by indirectly inhibiting glutamate signaling. They were originally developed as antiseizure drugs and were later found to be helpful in neuropathic pain and several other neurologic disorders (Varadi 2024). More recently, several gabapentinoids have been found to be safe and effective in RLS patients, including some whose symptoms have been exacerbated by dopamine-enhancing treatment, and can have additional benefits in those with co-existing problems such as insomnia, chronic pain, anxiety, and impulse control disorders (Winkelman 2022; Pellitteri 2024).

Gabapentin (Neurontin) is a first-generation gabapentinoid and pregabalin (Lyrica) is second-generation. They are approved for treating epilepsy and various types of neuropathic pain (Varadi 2024). Their frequent off-label use for RLS is supported by randomized controlled trials demonstrating their ability to improve symptom severity and sleep quality (Winkelman 2025). Compared with gabapentin, pregabalin offers more predictable absorption with a similar safety profile (Winkelman 2025; Pellitteri 2024). Gabapentin enacarbil (Horizant) is a newer extended-release drug that is metabolized into active gabapentin in the body. It has been shown in multiple clinical trials to improve sleep quality, mood disturbances, and quality of life in RLS patients and is the only drug in this family currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe primary RLS in adults. It has better bioavailability and a more sustained action compared with regular gabapentin (Varadi 2024; Zhou 2021). Its high cost is a disadvantage (Winkelman 2025).

Gabapentinoids are safer than older first-line therapies that enhance dopamine signaling. Their most common adverse side effects are sleepiness and dizziness, but they can also worsen depression, metabolic disturbance, cognitive impairment, and risk of falling (Zhou 2021). Although gabapentinoids are generally not considered addictive, cases of withdrawal symptoms and physiologic dependence have been reported, mainly in patients with other substance use disorders (Bonnet 2018; Mersfelder 2016; Deng 2021). The FDA has further warned of possible central nervous system depression and serious breathing problems in patients with respiratory conditions or when combined with other sedatives (FDA 2019).

Dopaminergic Agents

Drugs that increase dopamine signaling, including pramipexole (Mirapex), ropinirole (Requip), and transdermal rotigotine (Neupro), as well as levodopa plus carbidopa (Sinemet), were historically recommended as first-line therapies for RLS and have well-established efficacy (Dopp 2026; Zeng 2023). However, long-term regular use is strongly associated with augmentation, a phenomenon characterized by gradual and potentially irreversible worsening of symptoms. Although increasing the dose may provide brief symptom relief, it ultimately worsens augmentation (Winkelman 2025; Dopp 2026; Zeng 2023). Augmentation has been reported to affect 15–30% of those treated with dopaminergic agents for two to three years and 42–68% of those treated for around 10 years (Zeng 2023).

Dopaminergic drugs are also known to cause sudden episodes of extreme sleepiness and compulsive behaviors, such as gambling, shopping, and eating, especially when used at high doses (Winkelman 2026; Dopp 2026). Furthermore, drug discontinuation may provoke severe rebound symptoms, and prior dopaminergic therapy has been associated in some studies with diminished response to other treatments such as gabapentinoids (Winkelman 2025).

In light of these risks, the AASM no longer recommends dopaminergic agents as first-line therapies in long-term management of RLS. Short-term use of the lowest effective dose may be a reasonable option for patients with occasional or infrequent need or those who have not responded to safer therapies, but close monitoring for augmentation and other side effects is essential (Winkelman 2025). Furthermore, the AASM guidelines strongly recommend against the use of cabergoline (Dostinex), an ergot-derived dopamine agonist, for RLS. Despite its efficacy, long-term cabergoline use has been linked not only with augmentation but also with cardiac valve thickening and dysfunction, which can lead to serious cardiac complications (the literature includes one case report of death due to cabergoline-induced valvulopathy) (Winkelman 2025; Budayr 2020; Hayes 2023).

Opioids

Opioids (ie, analgesics used mainly to treat intractable pain) are a recommended option for treating RLS that is unresponsive to other therapies or in patients with augmentation from dopamine agonist therapy (Winkelman 2025). A study that analyzed data from 500 subjects taking low-dose opioids (mainly methadone [Methadose or Dolophine] or oxycodone [Oxycontin]) for long-term management of RLS suggested this approach can be effective (Winkelman 2021). A randomized controlled trial in 276 RLS patients who had not responded to other therapies found 12 weeks of treatment with prolonged-release oxycodone–naloxone was more effective than placebo for reducing symptom severity and increasing quality of life; however, 13% of participants in the treatment group withdrew due to tolerability problems compared with 7% in the placebo group (Trenkwalder 2013). Opioids can also cause constipation, sleepiness, itching, and sweating (Winkelman 2026). Due to their well-known propensity to cause tolerance, addiction, and overdose, opioids should be used cautiously (Winkelman 2025).

Dipyridamole

Dipyridamole (Persantine) is an antiplatelet agent and coronary artery vasodilator used historically to treat coronary artery disease and prevent blood clots. Dipyridamole increases adenosine availability and has been studied as an emerging treatment for RLS (Allahham 2022; Yeh 2023). In an open-label uncontrolled clinical trial in 13 subjects with RLS, six participants had a 50% or greater reduction in symptom scores after eight weeks of treatment with dipyridamole and four participants experienced a smaller degree of improvement (Garcia-Borreguero 2018). The same research group conducted a randomized, placebo-controlled, crossover trial in 28 RLS patients and found symptoms improved more after two weeks of treatment with dipyridamole than placebo (Garcia-Borreguero 2021). Reported side effects included abdominal bloating, cramping, diarrhea, dizziness, flushing, and weakness or fatigue (Garcia-Borreguero 2018; Garcia-Borreguero 2021). Based on this emerging evidence, the AASM recommended dipyridamole as an option for RLS patients who have not responded to first-line gabapentinoids (Winkelman 2025).

Benzodiazepines

Benzodiazepines are sedatives that work by enhancing the activity of gamma aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the brain that counterbalances the effects of glutamate (Sears 2021). Benzodiazepines are widely used to treat anxiety and sleep disorders, and a number of clinical trials in RLS patients, most of which were uncontrolled, have indicated a drug in this class—clonazepam (Klonopin)—may be effective for reducing symptoms. In addition to a lack of high-quality evidence of benefit in RLS sufferers, benzodiazepines have well-known side effects that limit their use, including daytime sedation, cognitive impairment, instability and falls, tolerance and dependence, depression, and respiratory failure, particularly in older adults (Walters 2024). As a result of these concerns, the AASM recommended against the use of clonazepam in most cases of RLS (Winkelman 2025).

Other Drugs

Despite the availability of medications with established efficacy, a substantial proportion of RLS patients do not respond sufficiently or experience intolerable side effects. A number of other medications have some evidence suggesting they may benefit individuals with RLS (Yeh 2023). Among these, two antiseizure drugs, carbamazepine (Tegretol) and valproic acid (Depakene), and an antidepressant, bupropion (Wellbutrin), did not perform well in randomized controlled trials, leading the AASM to recommend against their routine use in the new guidelines (Winkelman 2025).

A 2023 review identified other medications with little or mixed evidence, including (Yeh 2023):

• Clonidine (Catapres), a drug that acts in the central nervous system to reduce sympathetic outflow, ultimately leading to effects such as decreased vascular resistance, reduced heart rate, and lower blood pressure
• Perampanel (Fycompa), amantadine (Gocovri), ketamine (Ketalar), and cannabinoids, which directly inhibit glutamate signaling
• Lamotrigine (Lamictal), topiramate (Topamax), oxcarbazepine (Trileptal), and levetiracetam (Keppra), which like gabapentinoids, are antiseizure drugs

More research is needed to determine whether any of these medications can be considered as reasonable options in RLS treatment.

Stimulant Avoidance. Certain chemicals (e.g., nicotine and caffeine) stimulate both the central and peripheral nervous system, and can affect the body long after being ingested. As a result, many experts recommend that patients with RLS eliminate nicotine and avoid excess caffeine consumption throughout the day (Pigeon 2009; Bayard 2008). There is some controversy, however, regarding nicotine: there is a case report of nicotine actually helping alleviate symptoms in a patient (Oksenberg 2009), and another case report of exacerbation of RLS symptoms following smoking cessation (Juergens 2008). However, the evidence for nicotine as treatment for RLS is otherwise undocumented. In addition, excessive caffeine intake and nicotine use can also contribute to insomnia, which may exacerbate already existing RLS and increase daytime drowsiness.

Exercise. Increased physical activity may be one way for RLS patients to reduce their symptoms. Risk factors for RLS can include a lack of regular physical activity (Phillips 2000), higher BMI, and obesity (Ohayon 2002). A randomized controlled trial found that aerobic exercise and lower-body resistance training 3 days per week significantly reduced symptoms of RLS (Aukerman 2006). Regular physical activity improved sleep patterns and reduced periodic limb movements (PLM), and thus may be a useful non-pharmacological treatment for PLM (Esteves 2009). However, it is important to not engage in physical activity shortly before going to bed, as this can exacerbate RLS symptoms (Ohayon 2002).

Massage and Acupuncture. Both massage and acupuncture may produce some benefit for people with RLS (Stanislao 2009; Rajaram 2005; Russel 2006). A comprehensive review found that more research is needed to determine the benefit of acupuncture in RLS, as only two studies were deemed suitable for inclusion in the analysis (Cui 2008). However, one study did find that combining dermal needle therapy with medications and massage was more effective than medications and massage alone (Zhou 2002). Similarly, massage of the affected regions of the leg may provide counter stimuli that can alleviate RLS symptoms (Gamaldo 2006). Other massage techniques (e.g., myofascial release, trigger point therapy, deep tissue massage), and enhanced external counter pulsation may also relieve RLS symptoms (Rajaram 2005; Russel 2006).

Iron. Due to the presumed link between iron deficiency or altered iron metabolism in the brain and RLS (Conner 2008), one of the more common alternative treatments for RLS is iron supplementation (Trotti 2009).

Various routes for iron supplementation have been studied as a treatment for RLS. Oral iron supplementation has been found to significantly ameliorate RLS in patients with low-normal levels of iron in their blood (Wang 2009). However, it is unclear if oral iron supplements are as effective for patients with no signs of iron deficiency (Davis 2000). Oral iron supplementation is also beneficial for treating RLS in the elderly, particularly those with low iron levels (O’Keeffe 1994). Intravenous iron supplementation in the form of iron dextran has also been found to significantly reduce RLS symptoms (Sloand 2004; Earley 2004). Although intravenous iron may be more effective than oral iron supplementation, it can cause severe complications including anaphylaxis (Silverstein 2004). It is important to note that only those with a blood test-verified iron deficiency should take supplemental iron. Ingestion of excess iron has been linked to cancer, atherosclerosis and other degenerative diseases.

Folate. Folate deficiencies may also play a role in the development of RLS. Pregnancy often precipitates signs of RLS (Manconi 2004) and folate levels are of paramount importance during pregnancy for healthy fetal development. Researchers have also found that pregnant women with low folate levels are more likely to develop RLS (Lee 2004), whereas women who take vitamins during pregnancy are less likely to develop RLS (Tunc 2007). Low levels of folate may also play a role in non-pregnant RLS patients (Patrick 2007). Older studies have found that folic acid supplementation can help treat certain paresthesias and other disorders of the peripheral nervous system as well (Botez 1976 and 1977).

Magnesium. Low levels of magnesium can cause neurons to become more easily excited, thus affecting a person’s mental status. As a result, magnesium supplements are often used to stabilize neuronal membranes and prevent abnormal activity in the nervous system (Trenkwalder 2008). Magnesium supplementation has been studied as a treatment for RLS. One case study found that magnesium supplements were able to relieve symptoms of RLS and improve sleep (Hornyak 1998). A novel form of magnesium – magnesium-l-threonate – may be even more effective for RLS because it is better able to gain access to the central nervous system (Slutsky 2010). However, the impact of magnesium-L-threonate on RLS has yet to be clinically validated.

Diosmin. The link between chronic venous disease and secondary RLS is well established (see above) (McDonagh 2007). Although it can be difficult to treat chronic venous issues, one therapy that has gained support is diosmin.

Diosmin is a natural venotonic that supports venous function, thereby preventing or reversing some of the changes of chronic venous disease (Carpentier 1998; Maksimovic 2008). Although the effectiveness of diosmin for treating RLS has not been tested, it remains a promising possible treatment.

Green Coffee Extract. Diabetes is a well-known risk factor for secondary RLS. However, less appreciated is that pre-diabetes – subclinical elevations in blood sugar – may also cause RLS while remaining under the diagnostic radar of most physicians (Gemignani 2007; Bosco 2009).

A study examining subjects with impaired glucose metabolism unearthed a significantly increased risk of RLS in this population. RLS affected 41% of those with pre-diabetes, while only 18% of those with healthy glucose tolerance experienced the condition (Bosco 2009).

Maintaining healthy glucose metabolism, even for those not diagnosed with diabetes, may be helpful in RLS. Even slightly elevated blood sugar can damage delicate nerve cells and contribute to unpleasant sensations called paresthesias (Yagihashi 2007). Life Extension suggests that all aging individuals should strive to maintain blood glucose levels between 80 and 86 mg/dL for optimal health. Green coffee extract, with minimal caffeine content, represents a powerful tool for those aiming to maintain healthy blood sugar levels. It may also help control glucose elevations, which have been associated with RLS. However, this theory has yet to be tested in clinical trials.

Valerian root. Often used as an herbal sedative, valerian root has shown promise at reducing symptom severity of RLS. In an 8-week clinical trial, supplementation with 800 mg of valerian root daily resulted in improvements in daytime sleepiness and RLS symptoms (Cuellar 2009). Additional data also support the effectiveness of valerian root in treating insomnia in postmenopausal women (Taavoni 2011).

French maritime pine bark. French maritime pine bark has been studied in the context of a wide variety of conditions, including vascular and circulatory health (Belcaro 2018a; Belcaro 2018b). It is commonly known as Pycnogenol—the trade name of a particular standardized extract that has been validated in many studies. Pycnogenol has been shown to decrease oxidative stress, improve endothelial function, and inhibit inflammation (Enseleit 2012; Nattagh-Eshtivani 2022).

A 2022 clinical study found Pycnogenol was effective at alleviating symptoms of RLS and improved venoarteriolar response (ie, a reflex that reduces limb blood perfusion to prevent edema) and microcirculation (Belcaro 2022). In this study, 45 healthy adults with RLS were assigned to receive either standard management of RLS (regimen consisting of eight hours of sleep daily, 20 minutes of mild exercise four times weekly, and vitamin C plus B vitamins) or standard management plus 150 mg Pycnogenol daily for four weeks. Participants were also given advice on maintaining good posture; wearing adequate shoes; and limiting consumption of caffeine, salt, and spicy foods. Treatment with standard management led to a non-significant improvement in symptoms, while treatment with Pycnogenol led to significant improvement in all assessed symptoms including itching, crawling, creeping, and throbbing sensations, as well as sleep problems. Importantly, 19 of 21 participants in the Pycnogenol group reported perceiving clear benefits of supplementation, while standard management alone led to only minor perceived benefits. In addition, Pycnogenol treatment normalized resting skin flux, which had been slightly elevated at baseline, while standard management did not. Elevated resting skin flux is associated with dysregulated microcirculation, as in conditions such as diabetic microangiopathy. Pycnogenol also significantly improved venoarteriolar response after four weeks, whereas standard management alone did not. Finally, Pycnogenol significantly reduced plasma free radicals (oxidative stress), minimal edema score, and lessened the need for use of analgesics. Pycnogenol was well-tolerated with no observed side effects.

Additionally, a two-part clinical trial demonstrated that Pycnogenol reduced muscle cramping and pain. In the first part, 66 healthy participants who regularly experienced muscle cramps took 200 mg Pycnogenol daily for four weeks with an additional follow-up on the fifth week. The number of cramps decreased from the two weeks before supplementation compared with after supplementing in normal, venous, and athletic participants. The beneficial effects were still seen in the week after stopping supplementation. In the second part of the study, 47 participants with intermittent claudication or diabetic microangiopathy took 200 mg Pycnogenol or placebo daily for four weeks. No effect was seen with placebo, whereas those taking Pycnogenol experienced significantly fewer cramps and reduced muscle pain (Vinciguerra 2006).